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Perspectives
T
here is little doubt that effective 
interventions against Plasmodium 
vivax are needed. An estimated 
2.6 billion people live in areas endemic 
for P. vivax [1], and P. vivax carries a 
substantial burden of disease with 50–70 
million clinical episodes each year [2]. 
A Blood-Stage Vaccine for P. vivax?
Effective malaria vaccines could act by 
preventing initial liver-stage infection 
and/or blood-stage replication of 
parasites. The attraction of targeting 
blood stages is that it is during these 
stages that disease occurs. Although 
Plasmodium parasites initially infect 
hepatocytes, this pre-erythrocytic stage of 
malaria infection passes silently without 
any illness, and disease results from 
unrestricted replication of parasites in 
the blood. Vaccines targeting the blood 
stage may not have to induce sterile 
immunity (immunity that prevents 
infection per se), which is challenging 
to achieve; effective control of parasite 
replication may be sufﬁcient to prevent 
illness and complications, as observed 
with naturally acquired immunity. 
Despite decades of research and 
early promise, there are still no 
effective malaria vaccines available. 
There are many reasons why 
development of malaria vaccines has 
been so difﬁcult. The multiple life 
cycle stages and estimated 5,000 genes 
of the parasite present a myriad of 
potential antigens, and it has been 
challenging to determine which of 
these antigens would make good 
vaccine targets. Additionally, antigens 
are highly polymorphic and expression 
and correct folding of recombinant 
proteins can be difﬁcult to achieve.
Duffy-Binding Protein as a Rational 
Vaccine Target
One antigen that stands out as an 
excellent vaccine candidate for P.
vivax is Duffy-binding protein (DBP). 
In a new study published in this issue 
of PLoS Medicine, Brian Grimberg and 
colleagues provide important data 
to support further research on this 
antigen as a possible vaccine candidate 
[3].
DBP is a member of a family of 
related proteins found across different 
malaria species that are involved 
in host-cell invasion and adhesion. 
In P. vivax and the closely related 
simian malaria P. knowlesi, DBP 
binds to Duffy antigen/receptor for 
chemokines (DARC) during parasite 
invasion of reticulocytes [4,5]. DARC 
is a blood group antigen, expressed 
on the surface of reticulocytes and 
erythrocytes, and can also function 
as a receptor for several chemokines. 
P. vivax DBP (PvDBP) appears to be 
essential for invasion, and resistance to 
P. vivax is conferred by a lack of DARC 
expression [6,7], a phenotype common 
throughout African populations. 
In the invasive merozoite form 
of the parasite, DBP is localized in 
apical secretory organelles known as 
micronemes [4], and is released just 
prior to the requirement for binding 
to DARC (Figure 1). This interaction 
is associated with the formation of 
a tight junction that moves over the 
surface of the merozoite as the parasite 
enters the erythrocyte. The solving 
of the DBP structure [8], combined 
with mutational analysis to identify key 
receptor-binding residues [9,10], has 
provided a sound understanding of the 
ligand–receptor interaction. 
Most notably, the receptor-
binding face of the protein has little 
polymorphism, whereas a region on an 
opposing face has many polymorphic 
residues, suggesting it is under selective 
pressure and is a target of acquired 
antibodies [8] (Figure 1). Hence it may 
be possible to develop a vaccine that 
predominantly targets the conserved 
region to block the PvDBP–DARC 
interaction.
Understanding Antibody Function
Antibodies to merozoite antigens 
of malaria are thought to play an 
important role in acquired immunity, 
and may act by inhibiting erythrocyte 
or reticulocyte invasion and subsequent 
replication of parasites. However, data 
on the inhibitory activity of antibodies 
are limited, particularly for P. vivax.
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Linked Research Article:
This Perspective discusses the 
following new study published in PLoS
Medicine:
Grimberg BT, Udomsangpetch R, 
Xainli J, McHenry A, Panichakul T, et 
al. (2007) Plasmodium vivax invasion 
of human erythrocytes inhibited by 
antibodies directed against the duffy 
binding protein. PLoS Med 4(12): e337. 
doi:10.1371/journal.pmed.0040337
Christopher King and colleagues found 
that both rabbit and human antibodies 
inhibited binding of rPvDBPII to the Duffy 
antigen N-terminal region and to Duffy-
positive human erythrocytes, suggesting 
that a PvDBP-based vaccine may reduce 
blood stage Plasmodium vivax infection. 
The Perspectives section is for experts to discuss the 
clinical practice or public health implications of a 
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Simply measuring antibodies to 
recombinant merozoite proteins in 
standard immunoassays has signiﬁcant 
limitations, as recombinant antigens 
may not be in the same conformation 
or context as native protein. Standard 
immunoassays do not account for 
epitope speciﬁcity and antibody 
afﬁnity, which are likely to be essential 
for inhibitory activity. A barrier to the 
development and use of functional 
assays for P. vivax is the difﬁculty of 
culturing the parasite in vitro. P. vivax
does not efﬁciently invade mature 
erythrocytes, but instead is largely 
restricted to invasion of reticulocytes. 
This property limits its capacity to cause 
severe malaria, but also makes it very 
difﬁcult to work with in the laboratory, 
which has held back progress on 
understanding P. vivax biology and 
vaccine development. However, recent 
approaches have been developed using 
cord blood or erythroid stem cells as a 
source of reticulocytes [11,12]. 
Grimberg and colleagues now show 
that antibodies to recombinant PvDBP 
generated by vaccination of rabbits or 
afﬁnity-puriﬁed from human serum 
can effectively inhibit reticulocyte 
invasion by P. vivax [3]. The same 
antibodies that inhibit invasion also 
inhibit binding of recombinant 
PvDBP to DARC. This suggests that 
the invasion-inhibitory activity of the 
antibodies is mediated by blocking 
the PvDBP–DARC interaction, and 
not by interfering with potential 
interactions that may occur between 
other molecules and PvDBP, or the 
PvDBP–DARC complex. 
Invasion inhibition by antibodies to 
PvDBP may seem somewhat surprising 
since, based on the structure of PvDBP, 
antibodies are predicted to target a 
region that is separate from the DARC 
binding site [8]. Given the extremely 
rapid process of invasion (about one 
minute [13]), and the fact that PvDBP 
is probably not released and exposed 
until attachment to reticulocytes, 
antibodies against PvDBP may have 
limited opportunity to exert a receptor-
blocking effect. However, until the 
molecular details of PvDBP–DARC 
binding are better understood, it is 
difﬁcult to conﬁdently predict the 
signiﬁcance of polymorphisms or the 
mechanism of antibody function. It is 
possible that the DARC and antibody 
binding sites have substantial overlap 
sufﬁcient for antibodies to inhibit 
binding [14]. 
These ﬁndings provide an important 
proof-of-concept that anti-PvDBP 
antibodies can inhibit merozoite 
invasion. Further studies are needed 
to: (1) understand the acquisition and 
induction of inhibitory antibodies; (2) 
relate the concentration of antibodies 
required for effective inhibition to 
antibody concentrations in vivo; and 
(3) determine the relationship between 
inhibitory antibodies and antibody 
reactivity in standard immunoassays 
using recombinant antigen. It would 
be valuable to learn whether antibodies 
that block recombinant PvDBP–DARC 
binding predict protection in human 
studies or animal challenge models.
Moving Forward to Vaccine Trials
Should a vaccine targeted to PvDBP 
now go forward to a phase I trial? 
Although PvDBP is a rational vaccine 
choice, there remain important issues 
to address. An effective vaccine may 
need to overcome signiﬁcant antigenic 
diversity in PvDBP. Grimberg and 
colleagues report that anti-PvDBP 
antibodies bound at similar levels to two 
different PvDBP variants. However, it 
will be important to extend this work to 
evaluate the effect of polymorphism on 
antibody inhibition. Others reported 
that some polymorphisms did affect 
the activity of antibodies that inhibit 
binding of PvDBP to DARC [15]. 
Another challenge is ﬁnding and 
evaluating suitable adjuvants that 
induce appropriate antibody responses 
and are safe for use in humans. Many 
animal vaccine studies are performed 
using powerful adjuvants that are not 
registered for use in humans. For 
example, a PvDBP vaccine in monkeys 
was partially effective with Freund’s 
adjuvant, which cannot be used in 
humans, but not with Montanide 
ISA720, which is licensed for human 
studies. Generating functional antibodies 
is an important vaccine objective and it 
would seem logical that the induction 
of invasion-inhibitory antibodies should 
be part of the criteria for a successful 
phase I PvDBP vaccine trial to proceed 
to phase II. Testing antibodies for 
inhibition of PvDBP–DARC binding 
may prove to be a suitable alternative for 
the more challenging live-cell invasion 
inhibition assay.  
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Figure 1. The role of Duffy-Binding Protein 
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